Lv2
150 积分 2022-10-24 加入
Estimating the starting dose for entry into humans: principles and practice
20天前
已完结
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
1个月前
已完结
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
2个月前
已完结
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
3个月前
已完结
CORR Insights®: Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
5个月前
已完结
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
6个月前
已完结
Cholangiocarcinoma Risk as Long‐term Outcome After Hepatic Resection in the Hepatolithiasis Patients
6个月前
已完结
Cholangiocarcinoma in Primary Sclerosing Cholangitis: Risk Factors and Clinical Presentation
6个月前
已完结
Cholangiocarcinoma — evolving concepts and therapeutic strategies
6个月前
已完结
Guillain–Barré syndrome
6个月前
已完结
皖公网安备34019202002308
